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OBJECTIVES: The NOS2 geneencodes for the inducible nitric oxide synthase(iNOS),responsible for nitricoxide (NO) production,
which contributes to antimicrobial and antipathogenic activities. Higher levels of both iNOS and NO-induced damage have been
observedininﬂammatoryboweldisease(IBD)patients.NOS2mayhavearoleinaspeciﬁcsubsetofIBDpatientswithsevereand/or
extensive colitis. Therefore, the aim of this study is to examine the role of NOS2 in such a subset, very early onset IBD (VEO-IBD).
METHODS: Seventeen tag single nucleotide polymorphisms (SNPs) in the NOS2 gene were successfully genotyped in VEO-IBD
patients. Genetic associations were replicated in an independent VEO-IBD cohort. Functional analysis for iNOS activity was
performed on the most signiﬁcantly associated functional variant.
RESULTS: The NOS2 rs2297518 SNP was found to be associated in VEO-IBD in two independent cohorts. Upon combined
analysis, a coding variant (S608L) showed the strongest association with VEO-IBD (Pcombined¼1.13 10
 6, OR (odds
ratio)¼3.398 (95% CI (conﬁdence interval) 2.02–5.717)) as well as associations with VEO-Crohn’s disease and VEO-ulcerative
colitis (UC). This variant also showed an association with UC diagnosed between 11 and 17 years of age but not with adult-onset
IBD (417 years). B-cell lymphoblastoid cell lines genotyped for the risk variant as well as Henle-407 cells transfected with a
plasmid construct with the risk variant showed higher NO production. Colonic biopsies of VEO-IBD patients showed higher
immunohistochemical staining of nitrotyrosine, indicating more nitrosative stress and tissue damage.
CONCLUSIONS: These studies suggest the importance of iNOS in genetic susceptibility to younger IBD presentation due to
higher NO production.
Clinical and Translational Gastroenterology (2014) 5, e46; doi:10.1038/ctg.2013.17; published online 16 January 2014
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INTRODUCTION
Very early onset inﬂammatory bowel disease (VEO-IBD),
according to the Paris Modiﬁcation to the Montreal classi-
ﬁcation, is described as IBD diagnosed in children under
the age of 10 years.
1 It is characterized by a higher tendency
for disease manifestation in the colon, more disease
extension, and a change in disease location over time.
2–5
Pediatric genome-wide association studies (GWAS)
have not focused on VEO-IBD;
6,7 however, candidate
gene studies have identiﬁed novel genetic variants that
are associated exclusively with VEO-IBD indicating that
very young children have unique genetic susceptibility
(reviewed in ref. 8).
Although the pathogenesis of IBD is multi-factorial, genetic
and functional studies have conﬁrmed the critical role of the
immune system in the pathogenesis of disease.
9 Encoded by
the NOS2 gene, inducible nitric oxide synthase (iNOS)
produces nitric oxide (NO) in response to pro-inﬂammatory
cytokines.
10 Although NO is a weak free radical,
11 it mediates
cell-damaging and toxic effects by forming peroxynitrite,
which contributes to DNA damage as well as protein damage
by combining with tyrosine to form nitrotyrosine (NT).
11,12
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www.nature.com/ctgBoth iNOS expression and NT staining have previously been
shown to be upregulated in the intestinal epithelium and
inﬂamed colonic mucosa of IBD patients.
10,11
Here, we report a genetic association with the NOS2
single nucleotide polymorphisms (SNPs) and VEO-IBD,
VEO-Crohn’s disease (CD), and VEO-ulcerative colitis (UC).
In addition, we found a strong age-biased association
between the iNOS variant, rs2297518 (S608L), and
VEO-IBD. Last, we explored the function of this SNP and
found that it conferred higher NO production based on the
risk allele.
METHODS
SNP analysis and genotyping. Eighteen tag SNPs provid-
ing complete genetic coverage of the NOS2 gene (chromo-
some 17, 26,083,792-26,127,555) were selected from the
International HapMap Project (www.hapmap.org) Caucasian
(CEU) phase II data Release 23a (minor allelic frequency
41%). The Illumina Goldengate Custom Chip (discovery
cohort) as previously described
13,14 and Taqman (for
replication of the two most signiﬁcant SNPs from the
discovery cohort) were used at the Centre for Applied
Genomics, Hospital for Sick Children.
Subjects. All VEO-IBD subjects had a conﬁrmed diagnosis
of IBD before the age of 10 based on the Paris classiﬁcation.
1
Phenotypic information and DNA samples were obtained
from study subjects with approval of the institutional review
ethics board for IBD genetic studies at the Hospital for Sick
Children and Mount Sinai Hospital in Toronto. Replication
cohorts had ethics board approval for genetic and phenotypic
studies at the individual institutions. Written informed consent
was obtained from all participants.
The discovery cohort consisted of total of 1,072 subjects
including 159 VEO-IBD patients (91 VEO-CD and 68
VEO-UC)and 913healthy controlsrecruitedfrom theHospital
for Sick Children and Mt. Sinai Hospital in Toronto. The
replication cohort consisted of 736 subjects including 153
VEO-IBD patients (50 VEO-CD and 53 VEO-UC), and 480
healthy controls. The affected subjects were recruited from
NEOPICS sites (www.NEOPICS.org) and healthy controls
were obtained from the Centre for Applied Genomics (Ontario
Population Genomics Platform (plates used: 1–5; a complete
description of this control population can be found at http://
www.tcag.ca/cyto_population_control_DNA.html)). For the
analysis of older IBD groups, 498 IBD subjects (351 CD and
147 UC) diagnosed between 11 and 17 years of age and 918
IBD subjects (419 CD and 499 UC) diagnosed after 17 years
ofagewereincluded.Toconductsystematicqualitycontrolon
the raw genotyping data, we examined 770 SNPs genotyped
for the initial cohort only (18 SNPs genotyped in the initial
cohort). Detailed quality control has been previously reported
in detail elsewhere.
13,14 One NOS2 SNP, rs2297515, was
excluded as it deviated signiﬁcantly from Hardy–Weinberg
equilibrium in the controls (Po0.001). No other NOS2 SNP
was excluded due to a genotype call rate of o95%, or due to
sex discrepancies based on the heterozygosity rate from
SNPs on chromosome X.
Association analysis. Association analyses of the discov-
ery and replication cohorts were used to test associations of
the 17 NOS2 SNPs with VEO-IBD, VEO-CD, and VEO-UC
vs. healthy controls. Logistic regression analysis was applied
for an additive model and Pearson X
2 tests were applied
for dominant and recessive models. Models used to report
P values are described in this report. This analysis was done
using the Goldenhelix (SVS 7.6.4) program. The combined
cohort analysis pooled population data from both cohorts
and analyzed using the same protocol as for the individual
cohorts.
Cell culture. Genotyped B-lymphoblastoid cell lines were
obtained from Coriell Cell Repositories and cultured in RPMI-
1640X with 15% fetal bovine serum at 2 10
5 cells/ml in an
upright position at 5% CO2 and 371C. Supernatant was
collected for Griess assay. In addition, Henle-407 cells trans-
fected with the wild-type and S608L variant (designed
with Agilent Technologies QuickChange II Site-Directed
Mutagenesis Kit, according to the manufacturer’s instruc-
tions) of the iNOS-pcDNA3 were cultured in Dulbecco’s
modiﬁed Eagle’s medium with 10% fetal bovine serum. The
Griess assay was performed using a Promega Griess Assay
kit (Madison, WI, USA), according to the manufacturer’s
instructions. Results were replicated. For the B-lymphoblas-
toid cell lines, absorption readings were taken at 570nm as
described by Uto et al.
15 iNOS expression in B-lymphoblas-
toid cells was measured by western blot analysis using
polyclonal Anti-Nitric Oxide Synthase 2 antibody (Boster
Biological Technology, Pleasanton, CA, USA) and iNOS-myc
expression in transfected Henle-407 cells was measured
using monoclonal Anti-Myc Tag antibody (Millipore, Billerica,
MA, USA; clone 4A6). Brieﬂy cells were grown in a 10-cm
dish, washed twice with 1  phosphate-buffered saline and
then lysed with standard protein lysis buffer (50mM Hepes,
pH 7.5, 150mM NaCl, 1.5mM MgCl2,1 m M ethylene glycol
tetraacetic acid, 10% glycerol, 1% Triton X-100), supple-
mented with 1mm phenylmethylsulfonyl ﬂuoride, 1mg/ml
aprotinin, 1mg/ml leupeptin, 1mg/ml pepstatin, and 1mM
vanadate. A total of 50ug of protein were used for western
blot analysis.
Immunohistochemistry. Formalin-ﬁxed, parafﬁn-embedded
colonic biopsy samples from six VEO-IBD patients (three with
major genotype and three with risk genotype) were obtained
from the Department of Pathology at the Hospital for Sick
Children with approval of the institutional review ethics board
for IBD genetic studies at the Hospital for Sick Children.
Location of biopsy samples and disease activity were matched
between the two groups by a pathologist. Immunohisto-
chemistry was performed with the SuperPicture 3rd Gen IHC
Detection Kit from Invitrogen (Carlsbad, CA, USA). Brieﬂy,
parafﬁn sections were deparafﬁnized using Xylene and
afterwards rehydrated with different percentages of ethanol.
Antigen retrieval step was performed with high pressure-
cooking, using 1mM EDTA, pH 9 with 0.05% Tween 20 as an
antigen retrieval buffer. Primary antibody incubation was
performed at 41C overnight. Subsequently, the sections were
washed three times with phosphate-buffered saline and
incubated with peroxidase quenching solution for 5min. The
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times with phosphate-buffered saline. HRP Polymer conjugate
incubation was 30min followed by three times washing with
phosphate-buffered saline, each time for 5min. 3,30-Diamino-
benzidine (DAB) chromogen was added to the sections for
1–5min. The sections were counterstained with Haematoxylin
and mounted with Entelan. NT staining was performed using
the polyclonal Anti-Nitrotyrosine antibody from Millipore (anti-
rabbit) at a dilution of 1:100.
Slides were scanned using a Zeiss Mirax Digital Slide
scanner. Acquired images were deconvolved into grayscale
DAB and haematoxylin channels using the Ruifrok and
Johnston method as described.
16 The staining intensity in
the DAB channel for each patient sample and control was
evaluatedusingImageJ software.Brieﬂy,a technicianblinded
to the patient diagnoses deﬁned regions of interest represent-
ing intestinal epithelia. Within each region of interest, the
NT-positive areas were deﬁned as regions containing pixels
with values 450. These regions were determined algorithmi-
cally using the ImageJ ‘Threshold’ function. Regions of
interest were converted to binary (where NT-positive regions
were deﬁned as 1.0; unstained regions were 0.0) and the
fraction of NT-positive area to total area (within each region of
interest) was determined. This method was repeated on
multiple sections for each patient.
RESULTS
NOS2 association with VEO-IBD. Seventeen tag SNPs in
the NOS2 gene were successfully genotyped in the VEO-IBD
discovery cohort of 159 VEO-IBD subjects and 913 healthy
control individuals (Table 1, Supplementary Table 1). We found
that rs2297518 (S608L) was associated with VEO-IBD, VEO-
CD, and VEO-UC (PIBD¼6.2 10
 6, OR (odds ratio) (95%
conﬁdence interval)¼4.4 (2.3–8.4)) (Supplementary Tables 2
and 3). This variant was also signiﬁcantly associated with
IBD diagnosed under the age of 6 years (Supplementary
Table 4), a more homogeneous phenotype of IBD patients
with a predominance of pancolitis.
17 In addition, rs1137933
was associated with VEO-IBD and VEO-UC (P¼7.43 
10
 4,O R ¼2.6 (1.5–4.6)). Both NOS2 variants showed a
stronger association with VEO-IBD than adult IBD as
observed here and in a previous study by Martin et al.
18
In an independent replication cohort, consisting of 153
VEO-IBD patients and 480 healthy controls, rs2297518 was
also associated with VEO-IBD with a combined analysis of
Pcombined¼1.13 10
 6;O R¼3.4 (2.0–5.7). The association
of rs1137933 with VEO-IBD did not replicate in this cohort;
however, remained signiﬁcant in the combined analysis
(Table 2).
In the analysis of older children and adults with IBD
(Supplementary Tables 5–10), NOS2 was associated
with UC diagnosed between 11 and 17 years of age (A1b,
Paris classiﬁcation; rs2297518; P¼9.65 10
 4,O R ¼3.3
(1.6–6.8); Supplementary Table 10) and not associated with
adult-onset IBD (417 years age group). This analysis
suggests that NOS2 variants are associated with VEO-IBD.
rs2297518 risk genotype is associated with higher
production of NO. As B-lymphoblastoid cell lines have
constitutive expression of iNOS,
19 supernatants from B-
lymphoblastoid cell lines genotyped for rs2297518, were
collected. To measure the NO production, NO
2 
2 levels,
indicative of NO production, were measured using the Griess
assay. Levels were compared among the three genotypes of
rs2297518, homozygous for the non-risk allele (G/G),
homozygous for the risk allele (A/A), and heterozygous
for both alleles (A/G). As shown in Figure 1a, cell lines
homozygous for the risk allele had signiﬁcantly higher
production of NO (one-way ANOVA, F(2,8)¼24.39;
P¼0.0026; Tukey’s HSD (honestly signiﬁcant difference)
test, Po0.05) indicating that leukocytes in patients homo-
zygous for the risk allele (iNOS S608L) have higher levels of
Table 1 Discovery cohort association analyses of 17 NOS2 SNPs with VEO-IBD
Recessive association
Chr. SNP Position MAF FU FA P-value OR L95 U95
17 rs2297518 23120724 0.18 0.23 0.17 6.2 10
 6 4.43 2.32 8.46
17 rs1137933 23130059 0.21 0.27 0.21 7.4 10
 4 2.64 1.50 4.65
17 rs9906835 23113501 0.42 0.38 0.43 0.39 0.81 0.51 1.29
17 rs944725 23133698 0.41 0.50 0.40 0.03 1.56 1.03 2.34
17 rs3730013 23150045 0.34 0.29 0.34 0.19 0.67 0.36 1.22
17 rs4795067 23130802 0.33 0.35 0.33 0.08 1.48 0.94 2.33
17 rs2297516 23119857 0.42 0.38 0.42 0.91 1.02 0.66 1.58
17 rs3794764 23135555 0.23 0.21 0.23 0.71 0.86 0.40 1.86
17 rs8072199 23140975 0.44 0.51 0.44 0.482 1.16 0.76 1.75
17 rs10459953 23151645 0.35 0.33 0.35 0.93 1.02 0.61 1.65
17 rs2314809 23119505 0.40 0.36 0.40 0.92 0.97 0.62 1.53
17 rs11080344 23128638 0.46 0.44 0.46 0.09 1.39 0.94 2.05
17 rs3794756 23110756 0.01 0.02 0.01 NA NA NA NA
17 rs3729508 23133157 0.40 0.38 0.40 0.96 1.01 0.64 1.58
17 rs11653716 23108659 0.032 0.05 0.03 NA NA NA NA
17 rs2314810 23128237 0.04 0.04 0.04 0.56 1.93 0.19 18.71
17 rs3730017 23133229 0.020 0.02 0.02 NA NA NA NA
FA, frequency affected; FU, frequency unaffected; L95 and U95, lower and upper 95th conﬁdence interval; MAF, minor allelic frequency.
P values are presented as uncorrected and recessive modeling.
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As shown by the imputation analysis (Supplementary
Table 13), B-lymphoblastoid cell lines genotyped for the
rs2297518 SNP do not have a signiﬁcant change in iNOS
expression.
20 Western blot for iNOS (Supplementary
Figure 1a), although expression varied between cell lines,
demonstrated no trend of expression changes among the
three genotypes.
To explore the difference in the production of NO in human
intestinal epithelial-derived cells, Henle-407 cells were used
to study the difference in NO production between the major
and risk variants of rs2297518. As shown in Figure 1b, cells




the wild-type variant (Po0.05). This result further suggests
that this coding variant alters iNOS protein function. Western
blot for iNOS in transfected cells (Supplementary Figure 1b)
conﬁrmed that this difference was not due to an iNOS
expression difference.
Patients with rs2297518 risk genotype show higher
peroxynitrite levels in colonic biopsies. To assess any
change in peroxynitrite levels in these patients, colonic
biopsies from genotyped patients were stained with anti-
bodies to NT, which is formed by nitrosylation of tyrosine
residues due to peroxynitrite.
12 Consistent with Griess assay
results from the genotyped B-lymphoblastoid cell lines and
transfected Henle-407 cells, VEO-IBD patients with the risk
genotype of rs2297518 were shown to have higher levels of
NT staining (Figure 2, Supplementary Figure 2). It is
suggested that this is indicative of higher levels of nitrosative
stress and damage in patients with the risk genotype.
Although overall levels observed varied due to differences
among individual patients and cases, NT staining was
consistently more pronounced in both the epithelial (crypt
cells and brush border) and leukocyte inﬁltrate.
DISCUSSION
iNOS is expressed in inﬂamed tissues and there is a known
correlation between higher iNOS expression and colitis
although the mechanism is unknown.
10 Here we report that
both rs2297518 and rs1137933 were found to be associated
with VEO-IBD. Although previously reported in adults,
18 this
association was not replicated in recent adult-onset IBD
GWAS and meta-analysis, where rs2297518 was not asso-
ciated with either CD or UC, and rs1137933 was not included
in the meta-analysis (http://medicine.yale.edu/intmed/ibdgc/
index.aspx; Supplementary Tables 11 and 12).
21–23
Table 2 Replication and combined cohort analyses of NOS2 SNP associated with VEO-IBD
Replication analysis: VEO-IBD Combined analysis: VEO-IBD
SNP Diagnosis P-value OR (95% CI) P-value OR (95% CI)
rs2297518 VEO-IBD 0.04 2.4 (1.0–5.8) 1.13 10
 6 3.3 (2.0–5.7)
VEO-CD 0.51 1.6 (0.3–7.6) 1.19 10
 4 3.5 (1.7–6.8)
VEO-UC 0.18 2.3 (0.6–8.5) 4.81 10
 4 3.3 (1.6–7.0)
rs1137933 VEO-IBD 0.63 1.2 (0.4–3.3) 6.13 10
 3 1.9 (1.1–3.1)
VEO-CD 0.71 1.31(0.2–5.9) 0.02 2.0 (1.0–3.9)
VEO-UC 0.61 0.5 (0.7–4.5) 0.04 2.0 (0.9–4.0)
CD, Crohn’s disease; CI, conﬁdence interval; IBD, inﬂammatory bowel disease; OR, odds ratio; SNP, single nucleotide polymorphism; UC, ulcerative colitis.
P values are presented as uncorrected and recessive modeling.
Figure 1 (a) Griess assay results from the B-lymphoblastoid cell culture. G is
the non-risk allele and A is the risk-allele (N¼9). ANOVA testing (F(2,8)¼24.39;
P¼0.0026)revealedstatisticallysigniﬁcantvariancebetweenthegenotypes.Mean
NO2 production was not signiﬁcantly different between the AG and GG genotypes;
however,both genotypesweresigniﬁcantlydifferentfromtheAAgenotype(Tukey’s
HSD test; Po0.05). (b) Griess assay results from the transfected Henle-407 cells,
comparing constitutive expression of wild-type and S608L variants of iNOS
(Student’s t-test, n¼6, Po0.05).
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240.8) with rs2297518
(Supplementary Table 13) nor other NOS2 SNP were not
found to be associated with either CD or UC in the meta-
analyses. However, an NOS2 SNP, rs2945412, was found to
be associated with CD in the recent adult-onset IBD meta-
analyses indicating that common variants in NOS2 may also
be associated with adult-onset IBD.
21 Current estimates
suggest that adult-onset IBD GWAS have explained
B23–33% of the inherited contribution to IBD risk.
21–23
Therefore, there remains substantial ‘missing heritability’ that
will not be fully explained by simply expanding the GWAS
approach with larger numbers of patients.
22 Our candidate
gene approach using a speciﬁc extreme IBD phenotype,
VEO-IBD in this case, may allow for the identiﬁcation of novel
susceptibility loci not found in GWAS and allow for further
understanding of the genetic basis of IBD. Here we observed
associations between rs2297518 and VEO-IBD, VEO-CD,
and VEO-UC as well as an association with UC between 11
and 17 years of age. This age-biased association indicates
the functional signiﬁcance of this variant as well as the
importance of iNOS activity in the susceptibility to younger
disease presentation. However, there are limitations to the
studyincludingthesmallsamplesizecomparedwithadultIBD
genetic studies and variability in inﬂammation and iNOS
staining in our patient population.
A number of inﬂammatory diseases have overlapping
genetic susceptibility with IBD
24 and rs2297518 (S608L) has
also been implicated in the susceptibility of type 1 diabetes,
severe asthma, and atrophic gastritis.
25 Interestingly, the
above diseases all have inﬂammatory or autoimmune
phenotypes, indicating that an increase in iNOS activity may
contribute to the pathogenesis of these diseases. The
rs2297518 risk allele results in a S608L amino-acid change
that is located in the catalytic domain of iNOS and
Johannesen et al.
26 suggest that this S608L substitution
may affect the catalytic activity of iNOS, as it is close in
proximity to the Flavin mononucleotide-binding region. This
risk genotype of rs2297518 also resulted in higher iNOS
activity in both genotyped B-lymphoblastoid cell lines as well
as plasmid vector-transfected Henle-407 cells, as measured
by the Griess assay. The higher iNOS activity observed was
further supported by higher levels of NT staining in colonic
biopsies of VEO-IBD patients with the risk genotype,
suggesting thatthe higher NO production from this risk variant
contributes to higher nitrosative stress and peroxynitrite
damage in the intestines of IBD patients. As younger pediatric
IBD patients (both CD and UC) often present with severe
pancolitis
3–5 and iNOS expression is correlated to the
severity of colitis in UC patients,
10 the higher tissue damage
in these young children may explain the association of
rs2297518 with VEO-IBD as compared with adolescent- and
adult-onset IBD.
In an expression analysis from imputed genotypes (http://

















































Figure 2 (a). Immunohistochemistrystainingfor NTof parafﬁn-embeddedslidesofcolonicbiopsiesof VEO-IBDpatientsfromtheHospitalfor SickChildrengenotypedfor
the rs2297518 SNP. Shown is a representative image of VEO-IBD patients with non-risk (G/G) and risk genotypes (A/A). Images shown are taken at 10  magniﬁcation.
(b) Plotof area fraction (as %) describing NT-positiveregions as a ratio of the total tissuesection area in patientswith non-risk(G/G) andrisk (A/A) genotype (Student’st-test,
n¼3 per group, P¼0.02).
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expression (P¼6.0 10
 5). Arg2 protein is an inhibitor of
iNOS activity as it competes for L-arginine.
27 With respect to
gastrointestinal inﬂammation, it has been shown that Arg2
activity is induced in Helicobacter pylori-induced macro-
phages, which have reduced bacterial killing due to lower
iNOS translation.
28,29 As such, the higher iNOS activity
observed in VEO-IBD patients with the rs2297518 risk allele
may be due to the lower expression of the Arg2 that has been
shown to be associated with the NOS2 risk allele.
Internationally there is a documented rise in incidence of
pediatric IBD, with 77.8% of studies investigating this trend
reporting signiﬁcant increases.
30 In Ontario, this rise in
pediatric IBD has been shown to be due to the speciﬁc
increaseinincidenceofVEO-IBD,incontrasttotheagegroup
diagnosed between the ages of 11 and 17 years.
31 Pediatric
GWAS have not shown unique susceptibility loci compared
with adult-onset IBD;
6,7 however, these studies have focused
on older children with the disease diagnosed between 11 and
17 years of age and mostly excluded VEO-IBD. VEO-IBD is
considered a unique group of patients with a distinct
phenotype and novel genetic susceptibility.
8 This has been
demonstrated in recent studies showing that rare and private





examples have yielded the potential for personalized thera-
pies for severe and complicated VEO-IBD cases, it is possible
thatVEO-IBDpatientswithhigheractivityofiNOSmaybeneﬁt
from advancements in therapeutic inhibition of NO production
includingspeciﬁciNOSinhibitors,suchasN-[3-(aminomethyl)
benzyl] acetamidine (1400W) and L-N6-(1-iminoethyl)
lysine (L-NIL), which have been shown to have a protective
effect in rat 2,4,6-trinitrobenzenesulfonic colitis models.
11
Thus, we propose that NOS2 variants inﬂuencing higher
activity of iNOS contribute to the genetic susceptibility to
earlier onset of IBD due to NO-induced tissue damage and
intestinal inﬂammation.
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